Data Shows Voclosporin Preserves Kidney Function for Three Years
July 19,2023
The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus...
Lupkynis
Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis
September 21, 2022
Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults...
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
December 9, 2021
The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia...
Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting
November 9, 2021
Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College...
LRA Congratulates Aurinia on Published Results with FDA-Approved Lupkynis™
May 10, 2021
The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing...
Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback
April 20, 2021
At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an...
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
NEW YORK, NY. January...